Trial Profile
An exploratory phase IIIb, single-blind, outpatient study to assess next-day functioning in adult primary insomnia patients following the administration of NBI-34060 [indiplon] capsules during the night
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 14 May 2015
Price :
$35
*
At a glance
- Drugs Indiplon (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Neurocrine Biosciences
- 11 May 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 23 Jan 2008 updated status and actual end date according to nct dated 14 jan 08.
- 14 Jan 2008 Status changed from recruiting to discontinued.